EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Emerging nanoparticle-based therapies for pancreatic cancer: Current clinical landscape

Ainara Salgado-Pascual, Sara Zalba, Juan José Lasarte, Maria J Garrido

Advanced Drug Delivery Reviews · 2026-02 · 229 · 115760

DOI: 10.1016/j.addr.2025.115760 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2026-02. Verfasst von Ainara Salgado-Pascual und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain; Navarra Institute for Health Researc…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Nanoparticles, Antineoplastic Agents, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 204 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Instituto de Salud Carlos III, NextGenerationEU, Gobierno de Espana Ministerio de Ciencia e Innovacion.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic cancer, particularly ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal subtypes due to late diagnosis, the absence of early biomarkers, and the presence of a complex tumor microenvironment (TME). This TME is characterized by a dense desmoplastic stroma, hypovascularization, immunosuppression, and an acidic extracellular pH. All of these factors hinder the delivery and efficacy of conventional therapies, especially in advanced stages. Nanoparticles (NPs), including liposomes, polymeric micelles, albumin-bound particles and lipid nanoparticles, have emerged as a promising tool for overcoming TME barriers, and enhance drug delivery in tumor while minimizing systemic toxicity. NPs can exploit mechanisms such as the Enhanced Permeability and Retention (EPR) effect and active targeting. Clinically approved NPs such as Nab-Paclitaxel and liposomal Irinotecan have demonstrated improved pharmacokinetics and therapeutic benefits in PDAC. Furthermore, ongoing clinical trials are exploring novel NP-based strategies such as gene delivery, radiosensitization, immunomodulation and ferroptosis induction. Despite these promising advances, significant challenges remain, including poor tumor penetration, heterogeneity in EPR, and immune recognition of NPs leading to their clearance from bloodstream before reaching the tumor. Innovative solutions such as biomimetic coatings, stimuli-responsive systems and personalized formulations, are being evaluated to enhance NP performance. Standardization of NP characterization and data reporting are essential to accelerating clinical translation. The integration of artificial intelligence and machine learning could further optimize NP design and patient stratification. Overall, nanotechnology represents a crucial frontier of research for developing more effective and personalized pancreatic cancer treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsNanoparticlesAntineoplastic AgentsCarcinoma, Pancreatic DuctalNanoparticle Drug Delivery SystemHumansAnimalsTumor MicroenvironmentDrug Delivery Systems

Stichwörter der Autor:innen

Nanoparticles.Pancreatic cancerclinical traslationdesmoplastic stroma

Substanzen

Antineoplastic AgentsNanoparticle Drug Delivery System

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdisNA), Pamplona, Spain.
  • Program of Immunology and Immunotherapy, CIMA, CCUN-University of Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdisNA), Pamplona, Spain. Electronic address: jjlasarte@unav.es.
  • Department of Pharmaceutical Sciences, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdisNA), Pamplona, Spain. Electronic address: mgarrido@unav.es.

Förderung

  • Instituto de Salud Carlos III
  • NextGenerationEU
  • Gobierno de Espana Ministerio de Ciencia e Innovacion
  • European Commission

Zitieren

APA

Salgado-Pascual, A., Zalba, S., Lasarte, J. J., & Garrido, M. J. (2026). Emerging nanoparticle-based therapies for pancreatic cancer: Current clinical landscape. Advanced Drug Delivery Reviews, 229, 115760. https://doi.org/10.1016/j.addr.2025.115760

Vancouver

Salgado-Pascual A, Zalba S, Lasarte JJ, Garrido MJ. Emerging nanoparticle-based therapies for pancreatic cancer: Current clinical landscape. Advanced Drug Delivery Reviews. 2026;229:115760. doi:10.1016/j.addr.2025.115760

BibTeX
@article{SalgadoPascual2026,
  author = {Salgado-Pascual, Ainara and Zalba, Sara and Lasarte, Juan José and Garrido, Maria J},
  title = {Emerging nanoparticle-based therapies for pancreatic cancer: Current clinical landscape},
  journal = {Advanced Drug Delivery Reviews},
  year = {2026},
  volume = {229},
  pages = {115760},
  doi = {10.1016/j.addr.2025.115760}
}
Kostenlos starten →